[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-fractures\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-fractures":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100563176","naringenin-supplementation-in-bone-fracture-patients-100563176",false,"NCT06612762","Naringenin Supplementation in Bone Fracture Patients","Effect of Naringenin Supplementation on the Speed of Bone Fusion and the Concentration of Plasma Inflammatory Factors in Patients With Bone Fractures.","Inclusion Criteria:\n\n* Candidate for orthopedic surgery for bone fractures of the lower limbs,\n* Ambulatory without assistance for a minimum of two months prior to the fracture.\n* Not having undergone amputation of the lower limbs.\n* Not suffering from liver cirrhosis.\n* Not suffering from advanced kidney failure (blood creatinine higher than 1.4 mg\u002FdL).\n* Not having metastatic cancer, any chronic inflammatory diseases, nor taking any drugs that affect bone metabolism, including calcitonin, bisphosphonates, and corticosteroids.\n\nExclusion Criteria:\n\n* Allergy or intolerant reaction to narangenin capsules\n* Any abnormal changes in their liver, kidneys tests,\n* Failure to consume more than 10% of their capsules","ALL","18 Years","60 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","Fractures of the lower extremities represent a significant proportion of injuries sustained by polytrauma patients, with a notable association with prolonged hospitalization, chronic disability, and impaired physical functioning. The occurrence of surgical site infections (SSI) represents a significant threat to the efficacy of osteosynthesis procedures. As with other traumas and surgical procedures, the secretion of inflammatory mediators is markedly elevated in this cohort of patients following surgery. Naringenin is one of the most prevalent flavonoids, occurring naturally in grapefruit and other citrus fruits. In vitro studies have demonstrated that naringenin may stimulate the release of osteogenic cytokines and suppress the production of pro-inflammatory factors, which can result in a reduction in bone resorption. Based on these findings, naringenin may prove an effective agent for accelerating the rate of fusion and controlling inflammation. Furthermore, it may enhance quality of life and augment functional activity.",[27],"Bone Fractures","RECRUITING","2026-02-21",{"date":31,"type":32},"2026-02-24","ACTUAL",{"date":34,"type":32},"2024-11-03",{"date":36,"type":21},"2026-06-01",{"name":38,"class":39},"Shahid Beheshti University of Medical Sciences","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100561608","opioid-management-for-discharged-emergency-department-patients-100561608","NCT06592378","Opioid Management for Discharged Emergency Department Patients","Integration of an Opioid Dispensing, Monitoring, and Disposal Platform With a Hospital Pharmacy to Reduce Opioid Use by Discharged Emergency Department Patients","Inclusion Criteria:\n\n* Ages six years and older\n* Ability to swallow pills\n* Isolated bone fracture\n* Planned to receive opioids in the post-treatment period\n* Not taking opioids daily prior to the procedure\n* English or Spanish-speaking\n* Able to give informed consent or a parent that can give informed consent\n* Ownership of and comfort using apps on a smartphone with compatible operating system\n* WIFI or cellular access\n* Patient not admitted to hospital\n\nExclusion Criteria:\n\n* Recent opioid use (last 30 days or 2 or more prescriptions in the past 3 months\n* Impaired decisional capacity\n* In police custody\n* Ward of the state","6 Years",{"count":50,"type":21},100,[24],"The goal of this study is to analyze the use of the Addinex system for opioid dispensing after ambulatory care to determine whether it will reduce opioid consumption, increase pill disposal, show variables that may predict opioid consumption, and determine whether this intervention is acceptable to patients.",[27],[55,56,57],"opioids","fractures","pain","2025-12-24",{"date":60,"type":32},"2025-12-26",{"date":62,"type":32},"2025-06-27",{"date":64,"type":21},"2026-06-30",{"name":66,"class":67},"Addinex Technologies, Inc.","INDUSTRY",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100572683","study-on-safety-and-performance-of-advancore-bone-void-filler-100572683","NCT06736457","Study on Safety and Performance of AdvanCore Bone Void Filler","Inclusion Criteria:\n\n* Adult subjects ≥ 18 years old, male or female.\n* Subjects who are eligible for a bone grafting\u002Fbone void filler procedure.\n* Subjects with bone lesions beyond the limits of the bone's self-healing ability.\n* Subjects, and\u002For an authorized representative, who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center.\n* Subjects with only one fracture susceptible to treatment with an AdvanCore implant.\n\nExclusion Criteria:\n\n* Subjects with any AdvanCore contraindication for implantation or use.\n* Subjects with hypersensitivity to any of the AdvanCore components.\n* Subjects with infections or soft\u002Fgranulation tissue in the area to place bone graft.\n* Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study.\n* Women who are breastfeeding or of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion).",{"count":75,"type":21},190,[24],"The objective of this study is to evaluate the safety and performance of AdvanCore implantable bone graft through a 12-month follow-up period in a prospective, parallel-group design, non-controlled, open label, multi-center and real-world setting study. This study is intended to satisfy post-market clinical follow-up requirements of CE Mark in Europe.",[27,79,80,81],"Bone Defects","Bone Loss","Bone Graft",[83,84,85,86,87,88],"Bone graft","Bone substitute","Bone regeneration","AdvanCore","Beta-Tricalcium Phosphate","Synthetic bone graft","2025-05-30",{"date":91,"type":32},"2025-05-31",{"date":93,"type":32},"2025-05-29",{"date":95,"type":21},"2026-10",{"name":97,"class":67},"Artur Salgado SA",4]